Navigation Links
Will lung cancer recur? A genetic test may provide the answer
Date:5/19/2008

ATS 2008, TORONTOThe goal of developing reliable genetic tests to guide lung cancer treatment has taken a step forward. Researchers at Columbia University recently evaluated the ability of five high-risk genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non-small cell lung cancer was caught early and surgically removed. They will present their findings at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

Non-small cell lung cancer, which accounts for about 80 percent of all lung cancers, has a high rate of recurrence even when treated early, said lead researcher William Bulman, M.D. If we knew specifically in which patients the cancer was likely to come back, we could recommend more aggressive therapy to those patients. Dr. Bulman noted that genetic signatures for breast cancer are already commercially available and are used by physicians to guide treatment recommendations.

Dr. Bulman and his colleagues, Drs. Charles Powell and Alain Borczuk, tested five survival gene signatures in 21 patients, with squamous or adenocarinoma tumors who were followed for up to two years after their surgery. The accuracy of the tested signatures ranged from 40 to 80 percent and varied with the type of tumor. A 42-gene signature, for instance, was 82 percent accurate in predicting survival with lung adenocarcinoma, but only 70 percent accurate in predicting survival with squamous cell carcinoma.

Lung cancer is a heterogeneous disease, and information captured in these tests helps to distinguish tumors in terms of clinical outcomes. explained Dr. Bulman. Our findings not only indicate that genetic signatures have clinical utility in personalizing the treatment of lung cancer, but also that it may be necessary to use different gene-based risk predictors with different tumor subtypes.

Dr. Bulman noted that this research is part of a larger effort to understand the biological basis for why some early stage lung cancers progress and metastasize and why some do not. He added that he and his colleagues are planning to test these genetic signatures in new cohorts of patients for the purposes of targeting patients at high risk for recurrence.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Blood test for lung cancer may be possible
2. Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products
3. Protein Helps ID Thyroid Cancer Nodules
4. Kidney Cancers More Likely to Be Diagnosed Early
5. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
6. Majority of kidney cancers diagnosed at earliest stage
7. New data show benefit of finasteride in preventing prostate cancer
8. Cellvizio(R) Confocal Microscopy Improves ERCP Bile Duct Cancer Detection, According to New Study Presented at DDW
9. Prostate Cancer Vaccine Looks Promising in Early Trial
10. Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries
11. M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often ... it difficult for lab operators and management to assess these processes with a ... wasteful or unnecessary actions. , Created with the help of both internal ...
(Date:4/24/2017)... ... 2017 , ... “Reflections of God’s Work”: an enlightening collection of life lessons ... creation of published author, Jerri Broglin, a survivor of great loss who gained insight ... great eye-opener for those searching for answers, as we are finding the answers that ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held ... its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, FL. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a ... systems for the treatment of Acute Ischemic Stroke (AIS), today announced it has ... the product advances towards regulatory and clinical phases. , "This is another important ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
Breaking Medicine Technology: